July 31 - August 1, 2020

Live Webcast

All times will be in Pacific Time

The 19th Annual International Congress on the Future of Breast Cancer^® West will update clinicians on recent advances in the treatment of breast cancer, from breakthroughs in the lab to changes in treatment paradigms, focusing on the practical implications of emerging data for patient care in the clinic. Novel agents and improved regimens, coupled with more accurate molecular and phenotypic subtyping, are driving the future of breast cancer therapy. Recent data and their clinical impact are highlighted throughout the program, in the context of optimally individualizing breast cancer therapy. Current areas of controversy or uncertainty will also be debated, with discussion of ongoing clinical trials and investigational approaches designed to address these questions. This conference provides a unique opportunity for medical, surgical, and radiation oncologists and other healthcare professionals to learn from and interact with international leaders in the field of breast cancer in order to increase knowledge, apply new data to practice, and, ultimately, improve patient outcomes.

Physicians' Education Resource^®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource^®, LLC designates this live activity for a maximum of 14.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 14.25 Contact Hours.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

This activity provides Category I CME and self-assessment credits toward Part 2 of the ABS MOC Program. For more information, please visit www.absurgery.org

This activity is supported by educational grants from AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Puma Biotechnology; and Seattle Genetics.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Sara Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica – UCLA Outpatient Hematology/Oncology Practice
Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX